Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLL | Q9UGP5 | 1/20 | 0.33 |
| ▸ | MAP1LC3B | Q9GZQ8 | 4/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21014711 | 0.89 | TP53 (0.34) | MAP1LC3BMAPTLMNACYP2C9ALOX15 | |
| SCHEMBL24465254 | 0.87 | TP53 (0.37) | MAPTLMNACYP2C9ALOX15CYP2C19 | |
| SCHEMBL21134123 | 0.78 | MAP1LC3B (0.33) | MAP1LC3BMAPTLMNACYP2C9ALOX15 | |
| SCHEMBL27244319 | 0.78 | MAP1LC3B (0.33) | MAP1LC3BMAPTLMNACYP2C9ALOX15 | |
| SCHEMBL27244359 | 0.78 | MAP1LC3B (0.33) | MAP1LC3BMAPTLMNACYP2C9ALOX15 | |
| SCHEMBL27244325 | 0.78 | MAP1LC3B (0.33) | MAP1LC3BMAPTLMNACYP2C9ALOX15 | |
| SCHEMBL30989575 | 0.77 | MAP1LC3B (0.30) | MAP1LC3BMAPTLMNACYP2C9ALOX15 | |
| SCHEMBL30989573 | 0.74 | CCR6 (0.33) | MAP1LC3BMAPTLMNACYP2C9ALOX15 | |
| SCHEMBL14719952 | 0.72 | MAPT (0.43) | MAP1LC3BMAPTCYP2C9CYP2C19GAA | |
| SCHEMBL14719951 | 0.72 | MAPT (0.43) | MAP1LC3BMAPTCYP2C9CYP2C19GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119371-A1 | COMPOUND, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119371-A1 | COMPOUND, COMPOSITIONS, AND METHODS | LRRK2, PARK7, SNCA | POLL 4398/4885MAP1LC3B 115/4885MAPT 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.